71 related articles for article (PubMed ID: 8531092)
1. Pharmacology of a constitutively active muscarinic receptor generated by random mutagenesis.
Spalding TA; Burstein ES; Brauner-Osborne H; Hill-Eubanks D; Brann MR
J Pharmacol Exp Ther; 1995 Dec; 275(3):1274-9. PubMed ID: 8531092
[TBL] [Abstract][Full Text] [Related]
2. Constitutive activation of the m5 muscarinic receptor by a series of mutations at the extracellular end of transmembrane 6.
Spalding TA; Burstein ES; Wells JW; Brann MR
Biochemistry; 1997 Aug; 36(33):10109-16. PubMed ID: 9254607
[TBL] [Abstract][Full Text] [Related]
3. Differential modulation of agonist potency and receptor coupling by mutations of Ser388Tyr and Thr389Pro at the junction of transmembrane domain VI and the third extracellular loop of human M(1) muscarinic acetylcholine receptors.
Huang XP; Williams FE; Peseckis SM; Messer WS
Mol Pharmacol; 1999 Oct; 56(4):775-83. PubMed ID: 10496961
[TBL] [Abstract][Full Text] [Related]
4. Structure/function relationships of a G-protein coupling pocket formed by the third intracellular loop of the m5 muscarinic receptor.
Burstein ES; Spalding TA; Brann MR
Biochemistry; 1998 Mar; 37(12):4052-8. PubMed ID: 9521726
[TBL] [Abstract][Full Text] [Related]
5. Intramolecular interactions in muscarinic acetylcholine receptors studied with chimeric m2/m5 receptors.
Pittel Z; Wess J
Mol Pharmacol; 1994 Jan; 45(1):61-4. PubMed ID: 8302281
[TBL] [Abstract][Full Text] [Related]
6. Alanine scanning mutagenesis of conserved arginine/lysine-arginine/lysine-X-X-arginine/lysine G protein-activating motifs on m1 muscarinic acetylcholine receptors.
Lee NH; Geoghagen NS; Cheng E; Cline RT; Fraser CM
Mol Pharmacol; 1996 Jul; 50(1):140-8. PubMed ID: 8700106
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological characterization of human m1 muscarinic acetylcholine receptors with double mutations at the junction of TM VI and the third extracellular domain.
Huang XP; Williams FE; Peseckis SM; Messer WS
J Pharmacol Exp Ther; 1998 Sep; 286(3):1129-39. PubMed ID: 9732369
[TBL] [Abstract][Full Text] [Related]
8. Role of two highly conserved tyrosine residues in the m1 muscarinic receptor second transmembrane domain in ligand binding and receptor function.
Lee SY; Zhu SZ; el-Fakahany EE
Recept Signal Transduct; 1996; 6(1):43-52. PubMed ID: 8933621
[TBL] [Abstract][Full Text] [Related]
9. Muscarinic receptor function, density and G-protein coupling in the overactive diabetic rat bladder.
Stevens LA; Sellers DJ; McKay NG; Chapple CR; Chess-Williams R
Auton Autacoid Pharmacol; 2006 Jul; 26(3):303-9. PubMed ID: 16879496
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological comparison of the cloned human and rat M2 muscarinic receptor genes expressed in the murine fibroblast (B82) cell line.
Kovacs I; Yamamura HI; Waite SL; Varga EV; Roeske WR
J Pharmacol Exp Ther; 1998 Feb; 284(2):500-7. PubMed ID: 9454790
[TBL] [Abstract][Full Text] [Related]
11. Molecular basis of receptor/G protein coupling selectivity studied by coexpression of wild type and mutant m2 muscarinic receptors with mutant G alpha(q) subunits.
Kostenis E; Conklin BR; Wess J
Biochemistry; 1997 Feb; 36(6):1487-95. PubMed ID: 9063897
[TBL] [Abstract][Full Text] [Related]
12. Probing of the location of the allosteric site on m1 muscarinic receptors by site-directed mutagenesis.
Matsui H; Lazareno S; Birdsall NJ
Mol Pharmacol; 1995 Jan; 47(1):88-98. PubMed ID: 7838137
[TBL] [Abstract][Full Text] [Related]
13. Constitutive activity and inverse agonism at the M2 muscarinic acetylcholine receptor.
Nelson CP; Nahorski SR; Challiss RA
J Pharmacol Exp Ther; 2006 Jan; 316(1):279-88. PubMed ID: 16188951
[TBL] [Abstract][Full Text] [Related]
14. Generation of an agonistic binding site for blockers of the M(3) muscarinic acetylcholine receptor.
Thor D; Schulz A; Hermsdorf T; Schöneberg T
Biochem J; 2008 May; 412(1):103-12. PubMed ID: 18237275
[TBL] [Abstract][Full Text] [Related]
15. Single amino acid substitutions in the pm2 muscarinic receptor alter receptor/G protein coupling without changing physiological responses.
Bulseco DA; Schimerlik MI
Mol Pharmacol; 1996 Jan; 49(1):132-41. PubMed ID: 8569698
[TBL] [Abstract][Full Text] [Related]
16. Homologous mutations near the junction of the sixth transmembrane domain and the third extracellular loop lead to constitutive activity and enhanced agonist affinity at all muscarinic receptor subtypes.
Ford DJ; Essex A; Spalding TA; Burstein ES; Ellis J
J Pharmacol Exp Ther; 2002 Mar; 300(3):810-7. PubMed ID: 11861785
[TBL] [Abstract][Full Text] [Related]
17. Cysteine residues are involved in structure and function of melanocortin 1 receptor: Substitution of a cysteine residue in transmembrane segment two converts an agonist to antagonist.
Frändberg PA; Doufexis M; Kapas S; Chhajlani V
Biochem Biophys Res Commun; 2001 Mar; 281(4):851-7. PubMed ID: 11237737
[TBL] [Abstract][Full Text] [Related]
18. Two amino acids in the sixth transmembrane segment of the mouse gastrin-releasing peptide receptor are important for receptor activation.
Lin Y; Jian X; Lin Z; Kroog GS; Mantey S; Jensen RT; Battey J; Northup J
J Pharmacol Exp Ther; 2000 Sep; 294(3):1053-62. PubMed ID: 10945859
[TBL] [Abstract][Full Text] [Related]
19. Mutagenesis of residues adjacent to transmembrane prolines alters D1 dopamine receptor binding and signal transduction.
Cho W; Taylor LP; Akil H
Mol Pharmacol; 1996 Nov; 50(5):1338-45. PubMed ID: 8913366
[TBL] [Abstract][Full Text] [Related]
20. Binding sites and transduction process of the cholecystokininB receptor: involvement of highly conserved aromatic residues of the transmembrane domains evidenced by site-directed mutagenesis.
Jagerschmidt A; Guillaume N; Roques BP; Noble F
Mol Pharmacol; 1998 May; 53(5):878-85. PubMed ID: 9584214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
